Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions

Allogeneic Hematopoietic Cell Transplantation

Interventions

DRUG

Nicotinamide riboside (NR)

Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days

Trial Locations (1)

RECRUITING

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER